Dr. Cindy Jacobs discusses the commencement of the Phase 3 ORCA-2 Trial. ORCA-2 is currently enrolling 750 smokers at 15 clinical trial sites across the U.S. and will evaluate both 6 and 12 weeks of cytisinicline treatment compared to placebo.